EVs have been shown to interfere with antibody therapy in human epidermal growth factor receptor‐2 (HER‐2) overexpressing breast cancers, where the removal of HER‐2‐positive EVs was proposed to improve therapeutic outcomes.24 Here, ERBB2 is linked to breast carcinoma.